Gbert, Appreciate your efforts. My take is that insurance companies do not know nor do they care if they are infringing or not. Their goal is to reduce costs and ironically many generic Vascepa scrips may end up being filled as generic Lovaza because it is far cheaper than generic Vascepa. If they infringe with generic Vascepa they do not care as there is really no penalty for them...if they can get the scrip filled with generic Lovaza even better because that is really cheap. This is one more reason why AMRN should have been sold long ago to a BP that has the legal clout to go after infringers and might have the gravitas with the FDA to get them to enact an administrative solution to the problem. (My guess is for some reason JT is very fearful of the FDA and will not make any waves with them.) If Pfizer or JNJ owned this they would get the FDA to find a solution. What is strange is that this is a very real health issue with very real lives at stake...Should not the FDA be interested and take action? Why does that seem impossible for JT?
News 
Market Data 
Discover 
